Latest news with #exosomes
Cosmopolitan ME
03-07-2025
- Entertainment
- Cosmopolitan ME
Here's why this bride didn't wear foundation on her wedding day
Skipping foundation when going to the Mall of the Emirates is one thing, but on your wedding day? Unheard of. We sat down last week to chat with recent bride, Colette Laxton, who also happens to be co-founder of The Inkey List, about the brand's new Exosome Hydro-Glow Complex. She casually dropped into the convo that she didn't wear foundation on her wedding day. Naturally, we were blindedsided. It turns out that her bareface bridal beauty is connected to her new exosome-infused product drop. You might as well open the Sephora app now. We both know what you're about to do. Cosmo ME: What *exactly* are exosomes? Colette Laxton: Exosomes are tiny skin messengers that basically tell your cells to repair, renew, and glow up. They work incredibly hard, penetrate deep into skin, are non-irritating, and work well with other actives. Exosomes keep your skin strong, hydrated, and prepped for the long game. They provide prevention and glow, which I think is the dream. Cosmo ME: What kind of results can we expect when using exosomes? Colette Laxton: Skin will instantly have a smoother texture and glow. In the long term, it becomes stronger and more resilient skin. Cosmo ME: When are we supposed to use it? Day or night? Colette Laxton: You can use it both morning and night. I did just that every day for four months before my wedding. It's like a facial in a bottle. On my wedding day, my MUA said she wasn't putting foundation on my skin. Cosmo ME: Wait, what? Colette Laxton: My plan was always to get regular facials before my wedding. As I was using the Exosome Hydro-Glow Complex, I noticed skin was looking so glowy and smooth. Honestly, it looked the best it ever had, so I decided to skip the treatments. At my makeup trial, the artist used a thick foundation and by the end of the day, it had separated. On the wedding day, she told me she wasn't covering my skin up because it looked so beautiful. We only used just a bit of concealer under my eyes and around my redness. Cosmo ME: We need more details. What was your pre-wedding skincare routine? Colette Laxton: The same it is right now. I only use four products morning and night. They are our Milky Cleanser, which is being released in the GCC in the fall, Hyaluronic Acid, Exosome Hydro-Glow Complex, and Bio-Active Ceramide Moisturizer. Cosmo ME: Aside from being wowed by the power of exosomes, we were also stunned by your dress and its big bow. Not to mention, you married the man you founded the brand with! Spill the tea. Colette Laxton: I found my wedding dress on Instagram, of course. It's by Emilia Wickstead. The second I saw it, I knew it was for me. I wanted something strong, feminine, and unexpected. The big bow was like a power move. Supplied Mark is a microbiologist and I come from the branding side. He messaged me on LinkedIn and asked to meet for coffee. I got genius vibes from him but his communication needed some work. He had an idea for the brand and I knew if we teamed up, we could create something magical. We ended up falling in love. Cosmo ME: What a fairytale! Back to exosomes, how does The INKEY List keep consumers from getting overwhelmed by buzzy skincare ingredients? Sometimes it can be confusing if the latest ingredient is made for our skin, or not. Colette Laxton: We're all about education. Not every ingredient is meant for you. We have tools like Ask INKEY, where you can live chat with a skin expert. We also have a routine builder on our site used by over six million people. It gives you a customised routine based on your skin goals. Our packaging breaks it all down too and gives the deets on what it is, what it does, who it's for, and when to use it. The INKEY List's Exosome Hydro-Glow Complex is now available at Sephora. It's the skincare version of Colette's soft-girl power bridal gown. Want to know what other beauty products are new to the GCC? Dive into them right here.
Yahoo
17-06-2025
- Business
- Yahoo
Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology
Winner of the 'Biotherapies and Bioproduction' call for projects under the France 2030 plan, EVerZom receives €3 million in government funding to industrialize its exosome bioproduction technology Paris, June 17, 2025 – EVerZom, a French biopharmaceutical company pioneering exosome-based therapies for regenerative medicine applications, has announced it has received €3 million in funding as part of the France 2030 plan, through the 'Biotherapies and Bioproduction of Innovative Therapies' call for projects, operated by Bpifrance on behalf of the French government. This financial support will enable the company to accelerate the industrialization of its exosome bioproduction platform to develop its proprietary and co-developed drug candidates. Accelerating the transition to late-stage clinical production and commercialization This funding marks a key step in the company's industrial scale-up. It will notably allow for the scale-up of its exosome bioproduction technology in 50L GMP bioreactors, reaching a production level compatible with late-stage clinical phases and market launch. 'The French government 's support through the France 2030 'Biotherapies and Bioproduction' call is a strong recognition of our technology and industrial ambition. Thanks to this funding, we will secure a robust and scalable bioproduction process, which is essential to advance through late-stage clinical phases and prepare the market entry of our future proprietary or co-developed treatments,' said Jeanne Volatron, CEO of EVerZom. Exosomes at the heart of the development of promising new biotherapies Exosomes are tiny biological vesicles (30 to 150 nanometers) naturally secreted by cells. They play a key role in intercellular communication, transporting proteins, messenger RNAs, and other functional biomolecules between cells. EVerZom leverages exosomes derived from mesenchymal stem cells, known for their regenerative and immunomodulatory properties. Compared to the cells themselves, exosomes offer numerous advantages: increased stability, reduced variability, enhanced patient safety, and simplified logistics (direct hospital storage and immediate availability). EVerGel, EVerZom's first drug candidate for Crohn's disease EVerZom's flagship program, EVerGel, combines exosomes with an innovative hydrogel biomaterial, enabling prolonged release at the site of complex perianal fistulas—a debilitating condition associated with Crohn's disease that affects nearly 2 million patients worldwide. Initial preclinical results are highly promising: in a porcine model close to the human condition, EVerGel achieved complete healing in 87.5% of cases after 4 weeks, compared to just 12.5% in the control group. Thanks to these results, the drug candidate could enter clinical trials as early as 2026, with a target commercialization date for 2030. High potential far beyond the targeted indications Ultimately, the potential of exosome therapies to regenerate tissue and modulate inflammatory processes opens the door to new applications in a variety of fields, including neurodegenerative diseases, age-related disorders, and regenerative cosmetics. In this context, EVerZom has established around twenty global partnerships with players in human health, animal health, and cosmetics. Press contact : Florence Portejoie, FP2COM, 06 07 76 82 83, fportejoie@ About EVerZom Founded in 2019, EVerZom develops exosome-based treatments derived from mesenchymal stem cells, combined with biomaterials for targeted applications. With a proprietary technology for the production and purification of exosomes, EVerZom aims to address unmet medical needs in chronic inflammatory and degenerative diseases. The company relies on cutting-edge scientific expertise, a network of industrial and academic partners, and a development model focused on pharmaceutical quality and industrialization. This €3 million funding is part of the France 2030 plan, a French government initiative endowed with €54 billion to support breakthrough innovations and the emergence of technology champions in strategic sectors such as biotechnology. About France 2030 ✔ Embodies a dual ambition: to sustainably transform key sectors of our economy (health, energy, automotive, aerospace, and space) through technological innovation, and to position France not just as a player but as a leader in the world of tomorrow. From basic research to the emergence of an idea through to the production of a new product or service, France 2030 supports the entire innovation lifecycle up to industrialization. ✔ Is unprecedented in its scope: €54 billion are being invested to help our companies, universities, and research organizations successfully transition in these strategic sectors. The goal is to enable them to competitively tackle ecological and attractiveness challenges and foster the emergence of future leaders in our fields of excellence. France 2030 has two transversal objectives: dedicating 50% of its spending to the decarbonization of the economy and 50% to emerging players carrying innovations that are not harmful to the environment (in line with the Do No Significant Harm principle). ✔ Is implemented collectively: designed and deployed in consultation with economic, academic, local, and European stakeholders to determine strategic orientations and flagship actions. Project leaders are invited to submit their applications through open, rigorous, and selective procedures to benefit from State support. ✔ Is managed by the General Secretariat for Investment on behalf of the Prime Minister and implemented by the French Environment and Energy Management Agency (ADEME), the National Research Agency (ANR), Bpifrance, and the Banque des Territoires. More information: | @SGPI_avenir About the 'Innovations in Biotherapies and Bioproduction' call for projects The 'Innovations in Biotherapies and Bioproduction' call for projects is a support mechanism within the framework of the 'Biotherapies and Bioproduction of Innovative Therapies' acceleration strategy of France 2030, led by the Health Innovation Agency within the General Secretariat for Investment. Its objective is to catalyze and sustain excellence in biotherapy research by accelerating technology transfer and ensuring a constant flow of innovations from bench to bedside. About Bpifrance Bpifrance finances businesses at every stage of their development with loans, guarantees, and equity. It supports their innovation and international projects. Bpifrance also backs their export activities through a broad range of products. Advisory services, training, networking, and acceleration programs for startups, SMEs, and mid-caps are also part of the offering. Thanks to Bpifrance and its 50 regional offices, entrepreneurs benefit from a close, single, and efficient contact to support them and help them meet their challenges. More information: - - Follow us on X (formerly Twitter): @Bpifrance - @BpifrancePresse and on LinkedIn Attachment Everzom_PR_Winner_France_2030_VDEF
Khaleej Times
11-06-2025
- Business
- Khaleej Times
Future Health GCC Stem Cell Bank launches in-house GMP exosome production facility
Future Health GCC Stem Cell Bank, a recognised leader in stem cell banking and cellular science, has officially launched its new, in-house GMP (Good Manufacturing Practice) exosome production facility at its premises in Dubai Healthcare City. This milestone marks a significant advancement in the company's ongoing efforts to enhance its capabilities in biological processing and life sciences innovation. The newly developed facility enables Future Health GCC to produce GMP-compliant exosome preparations under strict international quality standards. This infrastructure supports a wide range of scientific and research-focused applications, reinforcing the company's position as a technology-forward organisation in the region. Exosomes, which are naturally occurring vesicles secreted by cells, are currently being explored globally for their role in intercellular communication and potential applications in research and biotechnology. Future Health GCC's initiative reflects its commitment to supporting this growing area of scientific study. 'The launch of our GMP exosome production facility is a key milestone that showcases our continuous investment in high-standard, advanced technologies,' said Ahmad Al Ahmad, CEO of Future Health GCC Stem Cell Bank. 'With this addition, we are proud to contribute to the development of the region's biotech infrastructure and facilitate future regenerative medicine' The facility is designed to accommodate scalable exosome production from various cell sources, with processes adhering to international GMP standards. All production batches are handled within tightly controlled environments, and finished products are stored in ultra-low temperature freezers at -80°C, monitored through a cloud-based temperature control system to ensure product consistency and integrity. The new facility will also enable collaboration opportunities with research institutions, biotech startups, and academic entities seeking reliable, quality-controlled exosome products for non-clinical and investigational use.
WIRED
30-05-2025
- Health
- WIRED
What Are Exosomes, and Why Are They in Your Skincare?
By now, you've probably seen 'exosomes' wafting across your For You Page, maybe sandwiched between a promo code for snail mucin and someone rendering beef tallow. Scroll through SkinTok long enough, and you'll hit a flood of videos hyping exosome therapy, exosome serums, and exosome treatments promising the skin health of a cherub. Skincare companies have seized the term. Marketed as miraculous regenerative agents, you'll find them on $300 facial menus, in post-micro-needling procedures, and across influencers' skincare routines. TikTok content This content can also be viewed on the site it originates from. What Are Exosomes? An exosome is a teeny sac inside a cell, or what a scientist might call an extracellular vesicle. They act as tiny mailbags, shuttling mRNAs, lipids, and other genetic material through the cell membranes from one cell to another. Exosomes are a part of the body's internal messaging system, regulating everything from cell growth to hormone production and gene expression. They're microscopic, measuring about 40 to 100 nanometers across, so small they make a red blood cell look massive in comparison. Scientists first discovered them under a microscope back in the 1960s, but they didn't gain significant attention until the early 2000s. Why Are Exosomes Controversial? In medicine, exosomes are being studied for cancer therapies, neurodegenerative diseases, and drug delivery systems. Because they reflect the state of the cells from which they originate, cancer cells often release exosomes that contain unique molecular fingerprints. Scientists are already using these biomarkers to assist in the early diagnosis of conditions like prostate cancer. The potential for early, non-invasive detection across a range of diseases is substantial. Because exosomes can cross biological barriers and deliver cargo, researchers are also exploring them as vehicles for targeted drugs. Additionally, they hold potential for wound healing, inflammation reduction, and tissue regeneration. Naturally, the beauty industry caught wind. Now, exosomes are in moisturizers, serums, and hair injectables, promising to repair your skin barrier, boost collagen production, and reverse aging.
Associated Press
23-05-2025
- Health
- Associated Press
R3 Stem Cell Publishes Podcast Called Stem Cell Genius to Educate Consumers on Regenerative Medicine
The world's largest provider of regenerative therapies, R3 Stem Cell, has launched a new podcast called Stem Cell Genius. 'With R3's Podcast Stem Cell Genius, we will provide accurate information to FAQ's in layman's terms so people understand what these wonderful stem cell and exosome therapies can or can't do!'— David Greene, MD, PhD, MBA SCOTTSDALE, AZ, UNITED STATES, May 23, 2025 / / -- The world's largest provider of regenerative therapies, R3 Stem Cell, has launched a new podcast called Stem Cell Genius. The podcast will touch on regenerative medicine subjects that will educate consumers on frequently asked questions and provide accurate information to delineate fact from fiction in the industry. The topics will be generated from the vast majority of frequently asked questions received on a daily basis. For instance, in the first episode R3 Stem Cell CEO David Greene, MD, PhD, MBA, explains the basics of what stem cells and exosomes are. In the second episode, Dr. Greene clarifies the differences between stem cells used in the USA versus internationally. According to Dr. Greene, 'There are so many questions surrounding stem cell therapy from the public, and unfortunately there are many unscrupulous actors spreading misinformation. With R3's President Samantha Brechner as the host, we will provide accurate information to FAQ's in layman's terms so people understand what these wonderful therapies can or can't do!' With over 26,000 stem cell procedures performed in the past decade, R3 Stem Cell has over 70 Centers in 7 countries. The company has published 10 peer reviewed research papers over the past 2 years, on regenerative therapies for conditions such as autism, Cerebral Palsy, premature ovarian failure, diabetes and more. With an incredibly broad experience, R3's CEO Dr. David Greene is able to convey a deep understanding of not just what the biologics are, but how they work for individuals and what to expect. Dr. Greene added, 'I'm not interested in fluff content involving stem cell research that won't help people. The topics are directly tied to existing therapies that are changing lives every day. For example, stem cell therapy for autism works amazingly well and is safe. Parents need the latest information to be able to make educated decisions regarding their child's healthcare.' R3 Stem Cell has stem cell clinics in Turkey, Philippines, Pakistan, India, Mexico, USA and South Africa. Each clinic utilizes R3's biologics and best practice protocols. New episodes will be added weekly, with the Stem Cell Genius podcast being available on all major content platforms. David Greene, MD, PhD, MBA R3 Stem Cell International +1 (888) 988-0515 email us here Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
